Then, the most cited publication (Olsson et al., 2016) further evaluated the diagnostic performance of many CSF and blood biomarkers for AD by conducting a meta-analysis, including GFAP in CSF, which implied the importance of GFAP for the diagnosis of AD. This evidence concerns the gene GFAP and Alzheimer disease.